Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons.

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental carcinogens and metabolized by a variety of xenobiotic-metabolizing enzymes such as cytochrome P450 (P450 or CYP), epoxide hydrolase, glutathione transferase, UDP-glucuronosyltransferase, sulfotransferase, NAD(P)H quinone oxidoreductase 1, and aldo-keto reductase. These enzymes mainly participate in the conversion of PAHs to more polar and water-soluble metabolites, and the resultant metabolites are readily excreted from the body. However, during the course of metabolism, a variety of unstable and reactive intermediates of PAHs are formed, and these metabolites attack DNA, causing cell toxicity and transformation. P450s and epoxide hydrolase convert PAHs to proximate carcinogenic metabolites, PAH-diols, and these products are further metabolized by P450s to ultimate carcinogenic metabolites, PAH diol-epoxides, or by aldo-keto reductase to reactive PAH o-quinones. PAHs are also activated by P450 and peroxidases to reactive radical cations that bind covalently to DNA. The oxygenated and reactive metabolites of PAHs are usually converted to more polar and detoxified products by phase II enzymes. Inter-individual differences exist in levels of expression and catalytic activities of a variety of enzymes that activate and/or detoxify PAHs in various organs of humans and these phenomena are thought to be critical in understanding the basis of individual differences in response to PAHs. Factors affecting such variations include induction and inhibition of enzymes by diverse chemicals and, more importantly, genetic polymorphisms of enzymes in humans.

[1]  H. Bartsch,et al.  Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers. , 1999, Cancer detection and prevention.

[2]  K. Dold,et al.  Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1 beta. , 1991, Science.

[3]  D. Nebert,et al.  Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. , 1982, Pharmacological reviews.

[4]  C. Guillemette,et al.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.

[5]  J. Williams Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. , 2001, Carcinogenesis.

[6]  D. Nebert,et al.  Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. , 1985, Nucleic acids research.

[7]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[8]  A. Luch,et al.  Comparison of cytochrome P450- and peroxidase-dependent metabolic activation of the potent carcinogen dibenzo[a,l]pyrene in human cell lines: formation of stable DNA adducts and absence of a detectable increase in apurinic sites. , 1999, Cancer research.

[9]  D. Jerina,et al.  Tumorigenicity studies with diol-epoxides of benzo(a)pyrene which indicate that (+/-)-trans-7beta,8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene is an ultimate carcinogen in newborn mice. , 1978, Cancer research.

[10]  K. Keyomarsi,et al.  Expression of cytochromes P450 in human breast tissue and tumors. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[11]  A. Jaiswal,et al.  NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y Fujii-Kuriyama,et al.  Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. , 2005, Biochemical and biophysical research communications.

[13]  H. Gelboin,et al.  Aryl hydrocarbon hydroxylase and polycyclic hydrocarbon tumorigenesis: effect of the enzyme inhibitor 7,8-benzoflavone on tumorigenesis and macromolecule binding. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Jennifer L. Martin,et al.  Human sulfotransferases and their role in chemical metabolism. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  S. Anttila,et al.  Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  B. Hammock,et al.  Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. , 2005, Annual review of pharmacology and toxicology.

[17]  Allan B. Okey,et al.  Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer* , 2004, Journal of Biological Chemistry.

[18]  P. Farmer,et al.  The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.

[19]  T. Sutter,et al.  Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. , 1998, Carcinogenesis.

[20]  T. Brüning,et al.  Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma. , 1999, Pharmacogenetics.

[21]  T. Shimada,et al.  Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1 , 2004, Cancer science.

[22]  A. Rettie,et al.  Functional analysis of human microsomal epoxide hydrolase genetic variants. , 2004, Chemico-biological interactions.

[23]  H. Swanson,et al.  Cloning and expression of a human Ah receptor cDNA. , 1993, Molecular pharmacology.

[24]  N. Ozawa,et al.  A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[alpha]anthracene. , 1982, Science.

[25]  J. Yokota,et al.  Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese Population , 1999, Japanese journal of cancer research : Gann.

[26]  M. Spitz,et al.  An association between a NQO1 genetic polymorphism and risk of lung cancer. , 2005, Mutation research.

[27]  O. Gotoh,et al.  Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. , 2000, Pharmacogenetics.

[28]  A. Conney,et al.  Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. , 1982, Cancer research.

[29]  A. Brøgger,et al.  Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. , 1991, Pharmacogenetics.

[30]  C. Ioannides METABOLIC-ACTIVATION OF POLYCYCLIC AROMATIC-HYDROCARBONS , 1988 .

[31]  A. Daly,et al.  Pharmacogenetics of the major polymorphic metabolizing enzymes , 2003, Fundamental & clinical pharmacology.

[32]  H. Kleiner,et al.  Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. , 2002, Chemical research in toxicology.

[33]  P. Harper,et al.  Polymorphisms in the human AH receptor. , 2002, Chemico-biological interactions.

[34]  N. Roodi,et al.  Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.

[35]  Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. , 1998 .

[36]  S. Amin,et al.  Tumorigenicity in newborn mice of fjord region and other sterically hindered diol epoxides of benzo[g]chrysene, dibenzo[a,l]pyrene (dibenzo[def,p]chrysene), 4H-cyclopenta[def]chrysene and fluoranthene. , 1995, Carcinogenesis.

[37]  S. London,et al.  Correspondence re: S. J. London et al., Lung Cancer Risk in African-Americans in Relation to a Race-specific CYP1A1 Polymorphism. Cancer Res., 55: 6035–6037, 1995. — Reply , 1996 .

[38]  T. Slaga,et al.  The effects of benzoflavones on polycyclic hydrocarbon metabolism and skin tumor initiation. , 1977, Chemico-biological interactions.

[39]  J. Schenkman,et al.  Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. , 2005, Archives of biochemistry and biophysics.

[40]  T. Slaga,et al.  Inhibition of the binding of 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene to DNA in mouse skin epidermis by 1-ethynylpyrene. , 1990, Carcinogenesis.

[41]  A. Olshan,et al.  Selected Genetic Polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and Risk of Head and Neck Cancer: A Pooled Analysis , 2005, Cancer Epidemiology Biomarkers & Prevention.

[42]  D. Nebert,et al.  Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate , 2006, Molecular Pharmacology.

[43]  R. Weinshilboum,et al.  Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. , 1999, Biochemical pharmacology.

[44]  R. Hayes,et al.  Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[45]  J. Freudenheim,et al.  Microsomal epoxide hydrolase variants are not associated with risk of breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  S. London,et al.  Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. , 1995, Cancer research.

[47]  H. Bartsch,et al.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[48]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.

[49]  D. Jerina,et al.  (+/-)-trans-7,8-dihydroxy-7,8-dihydrobenzo (a)pyrene: a potent skin carcinogen when applied topically to mice. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Yamazaki,et al.  Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. , 1997, Cancer research.

[51]  M. Manns,et al.  Polymorphisms of the Carcinogen Detoxifying UDP-Glucuronosyltransferase UGT1A7 in Proximal Digestive Tract Cancer , 2002, Zeitschrift fur Gastroenterologie.

[52]  L. Marnett,et al.  Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. , 1989, Cancer research.

[53]  J. Little,et al.  Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. , 2005, American journal of epidemiology.

[54]  A. Tjønneland,et al.  Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. , 2005, Cancer letters.

[55]  S. Lewis,et al.  Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. , 2001, Lung cancer.

[56]  C. Eap,et al.  Identification of a novel splice-site mutation in the CYP1A2 gene. , 2003, British journal of clinical pharmacology.

[57]  M. Spiteri,et al.  Glutathione-S-transferase family of enzymes. , 2001, Mutation research.

[58]  H. Yamazaki,et al.  Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[59]  T. Shimada,et al.  Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[60]  R. Weinshilboum,et al.  Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. , 1997, Biochemical and biophysical research communications.

[61]  T. Shimada,et al.  Recombinant Enzymes Overexpressed in Bacteria Show Broad Catalytic Specificity of Human Cytochrome P450 2W1 and Limited Activity of Human Cytochrome P450 2S1 , 2006, Molecular Pharmacology.

[62]  M. Tockman,et al.  Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk , 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[63]  X. Shu,et al.  Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[64]  C. Kiyohara Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. , 2000, Journal of epidemiology.

[65]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[66]  J. Ioannidis,et al.  Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[67]  P. Beaune,et al.  Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. , 1992, Molecular pharmacology.

[68]  C. Miller,et al.  Quantitative analysis of constitutive and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[69]  T. Shirakawa,et al.  Genetic polymorphisms and lung cancer susceptibility: a review. , 2002, Lung cancer.

[70]  F. Guengerich,et al.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. , 1985, The Journal of biological chemistry.

[71]  A. Luch,et al.  Metabolic activation of dibenzo[a,l]pyrene by human cytochrome P450 1A1 and P450 1B1 expressed in V79 Chinese hamster cells. , 1999, Chemical Research in Toxicology.

[72]  C. Griffin,et al.  Isolation and Characterization of the Human Cytochrome P450 CYP1B1 Gene* , 1996, The Journal of Biological Chemistry.

[73]  I. Roots,et al.  High frequency of CYP1A1 mutations in a Turkish population , 1998, Archives of Toxicology.

[74]  H. Kleiner,et al.  Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. , 2003, Chemical research in toxicology.

[75]  D. Nebert,et al.  Genetic mechanisms controlling the induction of polysubstrate monooxygenase (P-450) activities. , 1981, Annual review of pharmacology and toxicology.

[76]  J. Brockmöller,et al.  A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. , 1996, Cancer research.

[77]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[78]  Y Fujii-Kuriyama,et al.  Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. , 1994, The Journal of biological chemistry.

[79]  C. Jefcoate,et al.  A novel adrenocorticotropin-inducible cytochrome P450 from rat adrenal microsomes catalyzes polycyclic aromatic hydrocarbon metabolism. , 1991, Endocrinology.

[80]  F. Guengerich,et al.  Resveratrol is a selective human cytochrome P450 1A1 inhibitor. , 1999, Biochemical and biophysical research communications.

[81]  D. Nebert,et al.  Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse , 1975, Journal of cellular physiology.

[82]  K. Nakachi,et al.  Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. , 1991, Journal of biochemistry.

[83]  P. Workman,et al.  Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. , 2000, Molecular pharmacology.

[84]  T. Shirakawa,et al.  Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer , 2002, Environmental health and preventive medicine.

[85]  E. Schuetz,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. , 1992, Archives of biochemistry and biophysics.

[86]  Xinxin Ding,et al.  Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.

[87]  E. Taioli,et al.  A novel CYP1A1 gene polymorphism in African-Americans. , 1993, Carcinogenesis.

[88]  Xifeng Wu,et al.  Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. , 2003, Cancer letters.

[89]  D. Warshawsky,et al.  Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review. , 2005, Toxicology and applied pharmacology.

[90]  Y. Fujii‐Kuriyama,et al.  Functional role of AhR in the expression of toxic effects by TCDD. , 2003, Biochimica et biophysica acta.

[91]  E. Jabs,et al.  Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. , 1994, The Journal of biological chemistry.

[92]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[93]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Y. Fujii‐Kuriyama,et al.  P450 and Human Cancer , 1991, Japanese journal of cancer research : Gann.

[95]  T. Shimada,et al.  Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. , 1992, Cancer research.

[96]  S. Hecht,et al.  Tobacco smoke carcinogens and breast cancer , 2002, Environmental and molecular mutagenesis.

[97]  L. Marchand,et al.  Association of the NAD(P)H:quinone oxidoreductase 609C-->T polymorphism with a decreased lung cancer risk. , 1999, Cancer research.

[98]  C. Jefcoate,et al.  Ah receptor regulation of mouse Cyp1B1 is additionally modulated by a second novel complex that forms at two AhR response elements. , 2003, Toxicology and applied pharmacology.

[99]  D. Roop,et al.  NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. , 2000, Cancer research.

[100]  C. Tohyama,et al.  Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[101]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[102]  T. Shimada,et al.  Metabolic activation of environmental carcinogens and mutagens by human liver microsomes. Role of cytochrome P-450 homologous to a 3-methylcholanthrene-inducible isozyme in rat liver. , 1988, Biochemical pharmacology.

[103]  P. Watkins,et al.  THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.

[104]  F. Gonzalez,et al.  Targeted Disruption of the Microsomal Epoxide Hydrolase Gene , 1999, The Journal of Biological Chemistry.

[105]  T. Shimada,et al.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. , 1991, Chemical research in toxicology.

[106]  P. Harper,et al.  The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. , 1994, Toxicology letters.

[107]  T. Shimada,et al.  Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[108]  T. Shimada,et al.  Specificity of 17β-oestradiol and benzo[α]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432 , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[109]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[110]  H. Mohrenweiser,et al.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.

[111]  A. Spurdle,et al.  Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. , 2001, Carcinogenesis.

[112]  K. Nagata,et al.  Genetic polymorphism of human cytochrome p450 involved in drug metabolism. , 2002, Drug metabolism and pharmacokinetics.

[113]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[114]  E. LaVoie,et al.  Tumour initiating activity of dihydrodiols of benzo[b]fluoranthene, benzo[j]fluoranthene, and benzo[k]fluoranthene. , 1982, Carcinogenesis.

[115]  Teruhiko Yoshida,et al.  Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients , 2003, Journal of Pharmacology and Experimental Therapeutics.

[116]  M. Ingelman-Sundberg,et al.  In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. , 1997, Biochemical and biophysical research communications.

[117]  M. Spitz,et al.  Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. , 2002, Lung cancer.

[118]  K. Humphreys,et al.  Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. , 2003, Carcinogenesis.

[119]  Slobodan Petar Rendic Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[120]  E. Cavalieri,et al.  Identification and quantification of the depurinating DNA adducts formed in mouse skin treated with dibenzo[a,l]pyrene (DB[a,l]P) or its metabolites and in rat mammary gland treated with DB[a,l]P. , 2005, Chemical research in toxicology.

[121]  T. Shimada,et al.  Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. , 1999, Chemical research in toxicology.

[122]  N. Palackal,et al.  The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation. , 2001, Biochemistry.

[123]  K. Nakachi,et al.  Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. , 1993, Cancer research.

[124]  A. Luch,et al.  Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. , 2002, Chemical research in toxicology.

[125]  J. Liehr,et al.  4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[126]  J. Ferguson,et al.  Effect of a complex environmental mixture from coal tar containing polycyclic aromatic hydrocarbons (PAH) on the tumor initiation, PAH-DNA binding and metabolic activation of carcinogenic PAH in mouse epidermis. , 2001, Carcinogenesis.

[127]  E. Glover,et al.  Chlorinated biphenyl induction of aryl hydrocarbon hydroxylase activity: a study of the structure-activity relationship. , 1977, Molecular pharmacology.

[128]  T. Rebbeck,et al.  Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[129]  M. Ingelman-Sundberg,et al.  Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. , 1999, Drug metabolism reviews.

[130]  N. Hamajima,et al.  Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. , 2005, Gynecologic oncology.

[131]  E. Glover,et al.  Analysis of the four alleles of the murine aryl hydrocarbon receptor. , 1994, Molecular pharmacology.

[132]  T. Shimada,et al.  Dose-response studies on the induction of liver cytochromes P4501A1 and 1B1 by polycyclic aromatic hydrocarbons in arylhydrocarbon-responsive C57BL/6J mice , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[133]  M. Sarfarazi,et al.  Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. , 1997, Human molecular genetics.

[134]  Kazuo Komamura,et al.  Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[135]  D. Roop,et al.  NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. , 2001, Journal of the National Cancer Institute.

[136]  G. Coetzee,et al.  CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[137]  T. Penning,et al.  Aldo-keto reductases and formation of polycyclic aromatic hydrocarbon o-quinones. , 2004, Methods in enzymology.

[138]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. , 2003, Molecular pharmacology.

[139]  Á. Rodríguez-Lescure,et al.  Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. , 2002, Cancer letters.

[140]  H. Gelboin,et al.  Dimethylbenzanthracene Tumorigenesis and Aryl Hydrocarbon Hydroxylase in Mouse Skin: Inhibition by 7,8-Benzoflavone , 1970, Science.

[141]  T. Shimada,et al.  Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. , 2002, Carcinogenesis.

[142]  D. Nebert,et al.  Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.

[143]  Jingweng Wang,et al.  GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population. , 2003, Cancer letters.

[144]  D. Albanes,et al.  Polymorphisms in glutathione-S-transferase genes (GST-M1, GST-T1 and GST-P1) and susceptibility to prostate cancer among male smokers of the ATBC cancer prevention study , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[145]  R. Millikan,et al.  Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. , 2000, Cancer research.

[146]  D. Nebert,et al.  Human P(3)450: cDNA and complete protein sequence, repetitive Alu sequences in the 3' nontranslated region, and localization of gene to chromosome 15. , 1987, Journal of experimental pathology.

[147]  H. Ganther,et al.  Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. , 1994, Carcinogenesis.

[148]  Paolo Boffetta,et al.  Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review , 2002, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[149]  T. Penning,et al.  The aldo-keto reductase superfamily homepage. , 2003, Chemico-biological interactions.

[150]  J. Yokota,et al.  Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[151]  F. Guengerich,et al.  A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. , 2001, Cancer research.

[152]  Y. Fujii‐Kuriyama,et al.  Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. , 1995, Pharmacogenetics.

[153]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[154]  W. Levin,et al.  Purification and characterization of hepatic microsomal cytochrome P-450. , 1990, Pharmacology & therapeutics.

[155]  A. Child,et al.  Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. , 1998, American journal of human genetics.

[156]  T. Shimada,et al.  Tissue-specific induction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene. , 2003, Toxicology and applied pharmacology.

[157]  H. Echizen,et al.  Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients , 2003, Clinical pharmacology and therapeutics.

[158]  C. Jefcoate,et al.  Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. , 1990, Carcinogenesis.

[159]  G. Clark,et al.  Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals. , 1995, Carcinogenesis.

[160]  Y. Fujii‐Kuriyama,et al.  Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. , 1999, Genes & development.

[161]  H. Mukhtar,et al.  Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. , 1998, Biochemical pharmacology.

[162]  Trevor M Penning,et al.  Competing roles of cytochrome P450 1A1/1B1 and aldo-keto reductase 1A1 in the metabolic activation of (+/-)-7,8-dihydroxy-7,8-dihydro-benzo[a]pyrene in human bronchoalveolar cell extracts. , 2005, Chemical research in toxicology.

[163]  D. Ross,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. , 2004, Methods in enzymology.

[164]  K Chiba,et al.  Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.

[165]  F. Guengerich,et al.  Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. , 1996, Cancer research.

[166]  W. F. Greenlee,et al.  Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. , 2001, Annual review of pharmacology and toxicology.

[167]  W. Baer-Dubowska,et al.  Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. , 1997, Carcinogenesis.

[168]  J. Chang-Claude,et al.  SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case–control study , 2005, Breast Cancer Research.

[169]  J A McKay,et al.  Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.

[170]  T. Shimada,et al.  Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. , 2006, Chemical research in toxicology.

[171]  E. Taioli,et al.  A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. , 1995, Cancer research.

[172]  S. Anttila,et al.  Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. , 1997, Carcinogenesis.

[173]  H. Yamazaki,et al.  Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. , 1998, Chemical research in toxicology.

[174]  Y. Chun,et al.  Discovery of cytochrome P450 1B1 inhibitors as new promising anti‐cancer agents , 2003, Medicinal research reviews.

[175]  T. Slaga,et al.  Potent inhibitory effects of suicide inhibitors of P450 isozymes on 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene initiated skin tumors. , 1991, Carcinogenesis.

[176]  K Trieb,et al.  Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk , 2003, British Journal of Cancer.